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Summary We have assessed the pharmacokinetics, pharmacological and anti-tumour effects of the specific
steroidal anti-oestrogen ICI 182780 in 19 patients with advanced breast cancer resistant to tamoxifen. The
agent was administered as a monthly depot intramuscular injection. Peak levels of ICI 182780 occurred a
median of 8-9 days after dosing and then declined but were above the projected therapeutic threshold at day
28. Cmax during the first month was 10.5 ng/ml-' and during the sixth month was 12.6 ng ml-l. The AUCs
were 140.5 and 206.8 ng day ml-' on the first and sixth month of dosing respectively, suggesting some drug
accumulation. Luteinising hormone (LH) and follicle-stimulating hormone (FSH) levels rose after withdrawal
of tamoxifen and then plateaued, suggesting no effect ofICI 182780 on the pituitary-hypothalamic axis. There
were no significant changes in serum levels of prolactin, sex hormone-binding globulin (SHBG) or lipids. Side-
effects were infrequent. Hot-flushes and sweats were not induced and there was no apparent effect of treatment
upon the endometrium or vagina. Thirteen (69%) patients responded (seven had partial responses and six
showed 'no change' responses) to ICI 182780, after progression on tamoxifen, for a median duration of 25
months. Thus ICI 182780, given by monthly depot injection, and at the drug levels described, is an active
second-line anti-oestrogen without apparent negative effects on the liver, brain or genital tract and warrants
further evaluation in patients with advanced breast cancer.
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Half of the patients with advanced breast cancer have
tumours that either regress or remain stable when treated
with tamoxifen. Despite initial response all such tumours
eventually become resistant to this anti-oestrogen after a
median duration of remission of about 18 months (Cole et
al., 1971; Patterson et al., 1981). Although it acts as an
oestrogen antagonist with respect to the tumour, tamoxifen is
oestrogenic with respect to bone (Turken et al., 1989), the
liver (Bertelli et al., 1988) and the endometrium (Fornander
et al., 1989). Potential causes of treatment failure may result
from tamoxifen, or its metabolites (Osborne et al., 1991)
becoming oestrogenic with respect to the tumour (Howell et
al., 1990) or from tamoxifen becoming sequestered away
from the oestrogen receptor (ER) and rendered inactive
(Pavlick et al., 1992).
A new class of specific anti-oestrogens has been developed
that produce more complete suppression of the proliferative
effects of oestrogen upon tumours. Substitution of a long
side-chain at the 7 alpha position of the oestradiol molecule
has produced compounds that appear more active as anti-
oestrogens than the triphenylethylene derivatives such as
tamoxifen (Wakeling and Bowler, 1987, 1988). The structure
of the prototype specific anti-oestrogen, ICI 164384, is shown
in Figure 1 together with that of ICI 182780, {7a-
[9(4,4,5,5,pentafluoropentyl-sulphinyl)nonyl]oestra-1,3,5,(10)-
triene-3,17,B-diol} the compound selected for clinical evalua-
tion because of its greater potency and affinity for the ER
(Wakeling et al., 1991).
Both compounds have been assessed using in vitro and
animal models of human breast cancer and compared with
non-steroidal, partial agonist anti-oestrogens, including
tamoxifen, and also with oestrogen withdrawal. The specific
anti-oestrogens have shown superiority over these alternative
methods of oestrogen deprivation with respect to inhibition of
cell proliferation and oestrogen-induced gene expression. ICI
164384 and ICI 182780 are up to two orders of magnitude
more potent than tamoxifen as inhibitors of cell growth in
vitro. (Wakeling and Bowler, 1987, 1988) and produce a more
profound blockade of cell division in the GI phase of the cell
cycle. The specific anti-oestrogens are more effective than
tamoxifen in suppressing expression of oestrogen-induced
genes, such as progesterone receptor (PgR), pS2 and
cathepsin D (Nicholson et al., 1994) by breast cancer cells.
The specific anti-oestrogens have also been shown to produce
a rapid reduction ofintracellular ER levels, possibly as a result
ofinhibition ofER dimerisation and reduction ofthe ER half-
life (Fawell et al., 1990; Dauvois et al., 1992). This latter effect
is in contrast to that of tamoxifen, which has been shown to
increase ER expression by breast cancer cells in vitro
(Wakeling et al., 1989).
The experiments outlined above were performed on cell
lines but similar results were demonstrated when a short-
acting, propylene glycol-based formulation of ICI 182780 was
administered by daily intramuscular injection for 1 week
before surgery to women with primary breast cancer.
Compared with pretreatment tumour samples (obtained by
Tru-cut biopsy), those obtained after treatment with the
specific anti-oestrogen showed reduced proliferation (Ki67
expression) and reduced or absent expression of ER, PgR
and pS2 (DeFriend et al., 1994b; Nicholson et al., 1994).
Similar clinical experiments with tamoxifen produced no
change in ER expression, slightly increased PgR expression
and a reduction in labelling index (Howell et al., 1988;
Roberston et al., 1991; Clarke et al., 1993; Nicholson et al.,
1994).
The aims of the study reported here were to assess the
long-term efficacy and toxicity of the specific anti-oestrogen
ICI 182780 in patients with advanced breast cancer and to
evaluate the pharmacokinetics of the long-acting formulation
used. Since tamoxifen-resistant breast cancer cell lines have
been shown to retain sensitivity to specific anti-oestrogens
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when grown either in vitro (Lykkesfeld and Sorenson, 1992;
Brunner et al., 1993a,b; Lykkesfeld et al., 1994) or as
xenografts in nude mice in vivo (Gottardis et al., 1989;
Osborne et al., 1991), the effects of ICI 182780 were
evaluated in a group of post-menopausal patients with
tamoxifen-resistant breast cancer. Since the partial agonist
activity of tamoxifen on bone density and lipid levels has
been reported to the beneficial in post-menopausal patients,
the effects of ICI 182780 at other oestrogen target sites,
including the hypothalamus/pituitary gland, the liver and the
endometrium has also been assessed in this study.
We report that although some drug accumulation occurred
at the dose level used in this study, administration of ICI
182780 was associated with a lower than expected incidence
of side-effects (such as hot flushes and vaginal problems)
together with a high response rate and long response
duration in women previously treated with tamoxifen. A
preliminary report of the early clinical result of this study has
been published (Howell et al., 1995).
Patients and methods
Patients
Nineteen patients with advanced breast cancer resistant to
tamoxifen were treated with ICI 182780. The study was
approved by the ethics committees of each clinical centre.
Patients were eligible for the study if they were post-
menopausal and age less than 81 years, with histologically
verified breast cancer. Patients were included if they had been
treated with tamoxifen as an adjuvant to surgery for more
than 2 years and then relapsed, or if they had been treated
with tamoxifen for advanced disease, had a complete or
partial remission or disease stabilisation ('no change') for at
least 6 months, and subsequently progressed while taking
tamoxifen. Patients were excluded if they had serious
intercurrent disease, a WHO performance status of greater
than 2, and a life expectancy of less than 3 months or had
received previous cytotoxic chemotherapy for advanced
breast cancer. The characteristics of the patients studied are
summarised in Table I. One patient had adjuvant therapy for
only 9 months and progressed and was thus a protocol
violation, but is included in the analysis. She had progressive
disease when treated with ICI 182780.
Study design
After giving informed consent, all patients participating in
the study underwent baseline staging investigations before
commencing treatment with ICI 182780 including X-rays,
liver ultrasound or computerised tomography (CT) scan and
isotope bone scan. ICI 182780 was administered as a long-
acting formulation contained in a castor oil-based vehicle by
monthly i.m. injection (5 ml) into the buttock. For appraisal
of drug safety, the first four patients received escalating doses
of ICI 182780, starting with 100 mg in the first month and
increasing to 250 mg i.m. from the second month onwards,
following confirmation of lack of local or systemic drug
toxicity at the 100 mg dose. Patients 5-19 received
250 mg month-1 i.m. from the outset. Treatment with ICI
182780 was continued until objective tumour progression
occurred. Patients were seen at intervals of 3-7 days during
the first month after commencing treatment with ICI 182780
in order to monitor local and systemic drug tolerability and
to collect blood samples for pharmacokinetic studies.
Thereafter, patients were reviewed at monthly intervals in
order to evaluate objective tumour response to ICI 182780
and to further monitor local and systemic drug tolerability.
Blood samples were taken before commencing treatment with
ICI 182780 and at monthly intervals thereafter for
measurement of full blood count, clinical biochemistry and
serum hormone, SHBG and lipid levels. Tumour response to
therapy was evaluated according to UICC criteria (Hayward
et al., 1977). To qualify for the 'no change' category, tumour
growth had to stabilise for more than 6 months (Howell et
al., 1988; Robertson et al., 1989). Body weight was recorded
at each monthly review in the majority of patients.
Serum estimations
The concentration of ICI 182780 in serum samples was
determined by radioimmunoassay (RIA), using antibodies
raised in sheep to ICI 182780 coupled at the 17-position to
thyroglobulin and tritiated ICI 182780. The procedure was
applied after solid base clean up of a diethyl ether/hexane
extract of serum. The study limit of quantification was
0.68 ng ml-'. The RIA procedure is believed to be specific
for ICI 182780, since comparative analysis ofplasma samples
from preclinical studies by RIA and high-performance liquid
chromatography (HPLC) showed a good correlation for ICI
182780 concentrations. Further, ICI 182780 metabolites
present in these samples were not detected by the RIA.
Gonadotrophins follicle-stimulating hormone and lutenising
hormone (FSH and LH) and SHBG were measured by RIA
in the Regional Radioimmunoassay Laboratory of the
University Hospital of South Manchester. Prolactin was
measured by immunoradiometric assay using reagents
supplied by Netria. Total cholesterol levels were determined
enzymatically using a commercially available reagent
(Diamed, Switzerland). Triglyceride levels were determined
by the glyceryl phosphate oxidase-peroxidase-antiperox-
idase method using a commercially available kit (Boehringer
Mannheim, Germany). High-density lipoprotein (HDL)
cholesterol levels were measured after pretreatment of the
serum samples with buffered magnesium phosphotungstate,
which selectively precipitates low-density lipoprotein (LDL)
cholesterol, very low-density lipoprotein (VLDL) cholesterol
and chylomicrons, leaving HDL cholesterol in the super-
natant. Serum levels of LDL cholesterol were calculated
using the Friedewald equation (Friedewald et al., 1972).
Endometrial assessment
Endometrial thickness was measured in transverse section by
transabdominal ultrasound using a Siemens Sonoline SL2 with
a 3.5 MHz sector probe. Baseline and repeat scans at 3-6
monthly intervals were performed in five patients. Endometrial
histology was reviewed on one patient who had a hysterectomy
for uterine prolapse after 18 months on ICI 182780.ICI182780 and advanced breast cancer
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Table I Patient characteristics, tumour receptor status and response to ICI 182780
Duration Duration
Age at Time to ofadjuvant of tamoxifen Response to Sites of Response to Duration
No. entry relapse tamoxifen for adv tamoxifen disease ERl PR 182780 (months)
1 (ERD) 51 48 48 - Bone 0 0 PD <2
2 (PF) 75 - - 8 NC Breast 99 99 NC 29
Nodes
3 (SAS) 49 74 68 - - Lung 0 22 PR 12
Pleura
4 (AS) 53 45 45 - - Bone 16 0 PD <2
5 (AR) 68 20 20 - - Bone 74 <5 PR 8
Pleura
6 (FC) 58 77 77 - - Nodes 73 6 PR 3
7 (SC) 61 - - 8 PR Bone ND ND PD <2
Breast
8 (LH) 55 48 - 19 PR Breast 70 95 PR 25
Node
9 (NT) 70 42 9 - - Local 95 80 PD <2
Bone
10 (MC) 64 201 - 8 NC Local 100 100 PR 33+
11 (FWT) 70 271 - 7 NC Nodes 60 <5 PD <2
Bone
Breast
12 (MEU) 51 77 74 - Bone 99 97 NC 33+
13 (KG) 62 _ - 12 NC Nodes 90 60 PD <2
Bone
14 (IN) 78 120 - 24 PR Bone 100 0 PR 32+
15 (CA) 48 61 61 - Bone ND ND NC
16 (AC) 64 68 67 - Nodes 30 <5 PR 25
Breast
17 (LM) 67 52 - 34 NC Breast 70 30 NC 9
Bone
18 (JKJ) 65 80 - 48 NC Bone (1828)b (1) NC 30+
19 (MB) 64 23 23 - - Bone 29 29 NC 30+
I adv, advanced disease; PD, progressive disease; NC, no change; PR, partial response; ND, not done. a% cells positive, immunoassay.
bBiochemical assay (mol 1--1)
Statistical analysis
All statistical analyses were performed on an Apple
Macintosh personal computer, using the StatView SE
software programme (Abacus Concepts, Berkeley, CA,
USA). Pharmacokinectic data were analysed using para-
metric statistics. Data relating to body weight, serum
gonadotrophin, SHBG and lipid levels were analysed using
non-parametric statistics. The null hypothesis was rejected at
a probability level of P<0.05.
Results
Pharmacokinetics
Serum concentrations of ICI 182780 were measured during
the first month of treatment in 15 patients who started
treatment at the 250 mg dose level and in 11 patients who
remained on treatment with ICI 182780 during the sixth
month. In the majority of patients, the measured Cma,, was
reached 8 or 9 days after the start of the drug administration.
However, samples were not available between day 2 and day
8. The profile was quite flat between days 2 and 8, supported
by preclinical data in dogs where the Cmax was seen on day 1
or 2. Following both the 100 mg and 250 mg doses,
continuous release of drug from the ICI 182780 slow release
formulation was shown throughout the one month dosing
interval. The profiles of the serum concentration of ICI
182780 are shown in Figure 2. Comparison of data after the
first and sixth monthly 250 mg doses of ICI 182780 showed
that the mean exposure to the drug increased slightly after
multiple dosing. Mean Cm,, (which occurred on day 7)
increased from 10.5 ng ml-' to 12.8 ng ml-', accompanied
by increases in mean end-of-month concentrations from
3.1 ng ml-' to 5.6 ng ml-' and AUC values from
140.5 ng day ml-' to 206.8 ng day ml-' for the first and
sixth months respectively in the 11 patients studied. Multiple
dosing produced a 1.2-fold increase in Cma,, and a 1.5-fold
increase in AUC, indicating a degree of accumulation at the
250 mg dose level. This greater exposure was not associated
with any increased side-effects or irritancy (see below). There
was no significant difference in the median Cmax and AUC
between responders and non-responders to treatment (Table
II). After 6 months of treatment there was no significant
difference between Cmax and AUC for patients who had a
partial reponse (PR) compared with those with a no change
(NC) response.
Effects on hormones and lipids
The serum levels of FSH, LH, prolactin and SHBG, before
and during treatment with ICI 182780, are shown in Figure
3. The median levels of FSH and LH before starting
treatment with ICI 182780 were below the normal range for
post-menopausal women, whereas the median SHBG level
was above the normal range, both possibly related to theEi
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Figure 2 Mean serum concentrations of ICI 182780 during the
first and sixth months of treatment. , Profile at entry; -- -,
profile month 6.
agonist activity of previous treatment with tamoxifen. During
the first 3 months of administration of ICI 182780, there was
significant increases in the serum concentration of FSH
(median pre- and post-treatment values 26 and 52 IU l-1
respectively; P<0.05, Wilcoxon's matched-pairs signed-rank
test) and LH (median pre- and post-treatment values 26 and
42 IU 1-1 respectively; P<0.005). Thereafter, no further
significant overall changes occurred in serum gonadotrophin
levels but wide variation between individual patients were
observed, reflected in the broad interquartile ranges seen in
Figure 3. Serum SHBG levels showed an overall trend to
decrease following treatment with the specific anti-oestrogen,
falling from a median level of 100 mmol 1-' pretreatment to
55 mmol 1-1 after 8 months of treatment (P=NS. Figure 3c).
ICI182780 and advanced breast cancer
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This overall reduction appeared to result predominantly from
four patients who continued tamoxifen up to the time of
starting ICI 182780. The remaining patients, including 11
others on tamoxifen and four who had stopped tamoxifen
some time before entry, showed very little change in serum
SHBG levels during treatment. Serum prolactin levels
remained within the normal range, and did not change
significantly throughout the treatment period. There were no
significant changes in serum levels of total cholesterol, LDL
cholesterol, HDL cholesterol and triglyceride (Figure 3) for
the 12 patients treated in the South Manchester Breast Unit
during treatment with ICI 182780.
Side-effects
No serious drug-related adverse events occurred in any of
the 19 patients treated with ICI 182780. Minor systemic
adverse events were reported by two patients and
comprised a transient bloodstained vaginal discharge and
a subjective feeling of living in a 'dream-like state' (similar
to one she had while taking tamoxifen) in one patient and
alteration of body odour (noticed by her husband for a 1
month period), possibly associated with increased hair
greasiness, in the other. Administration of the pure anti-
oestrogen was not associated with any alteration in the
frequency of night sweats or hot flushes, if already present,
and none were initiated. None of the patients reported
vaginal dryness or altered libido despite direct questioning
at each monthly out-patient attendence. The long-acting
formulation of ICI 182780 used in this study appeared well
tolerated locally at the site of injection despite the relatively
large volume (5 ml) administered. One patient developed
bruising over the buttock and a second developed
tenderness at the injection site following drug administra-
tion on one occasion each, and a third patient had local
erythema at the injection site on one occasion. No
clinically significant changes in full blood count or
unexpected changes in the biochemical profile occurred in
any of the patients participating in the study.
Serial endometrial ultrasound examinations were per-
Table II Results of Cmax and AUC during months 1 and 6 according to response categories. There were no
significant differences in drug kinetics between responders and non-responders
On entry At month 6
Cma AUC Cmax AUC
Response Patient (ngmrl) (ngdaymrl) (ngmrl') (ngdayml-')
Progressive disease 1 4.4a 53.la
4 1.6a 25.la
7 5.5 105.7
9 9.7 138.2
11 29.9 289.3
13 5.6 36.7 15.8 243.7
Median 5.6 79.4
No change 2 1.8a 23.2a 7.5 135.8
12 7.2 143.6 12.2 179.3
15 9.0 107.8 15.8 201.7
17 9.5 125.5 14.9 297.6
18 10.3 183.2 10.2 156.1
19 11.0 137.8 17.2 308.0
Median 9.3 131.6 12.8 190.9
Partial response 3 2.9a 56.2a 9.9 139.5
5 17.4 188.4 17.6 203.0
6 7.7 118.3
8 5.9 118.7 10.0 175.2
10 14.8 206.6 9.1 191.7
14 9.1 134.6 13.5 266.0
16 4.4 72.8 12.0 190.8
Median 7.7 118.7 11.0 191.0
aPatients 1 -4 received 100mg dose at entry and 250mg dose from month 2 onwards.
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Figure 3 Median and interquartile ranges of lipids and hormones during treatment with ICI 182780. Numbers above the curves
refer to the numbers of patients tested. Twelve patients were tested for the four lipids (CHOL, cholesterol; TRIG, triglyceride;
HDLC, high-density lipoprotein; LDLC, low-density lipoprotein), 19 for the LH, FSH and SHBG and 13 for prolactin. Numbers
decline because patients go off study after progression.
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Table Ill Response rate and durations of response to ICI 182780 in
relation to duration of previous treatment with tamoxifen
Response
ICI182780 Number Durations (months)
(%)
Partial
Time (months)
Figure 4 Serial ultrasound estimations of endometrial thickness
in five patients. Thickened endometrium compared with normal
post-menopausal women was thought to be due to treatment with
tamoxifen. No significant change occurred up to 15 months of
treatment with ICI 182780.
formed in five responding patients. Endometrial thickness
was greater than the expected <2 mm usually found in post-
menopausal women, in all patients. The thickness of the
endometrium remained unchanged in all patients during
treatment with ICI 182780 (Figure 4). Endometrial histology
was reviewed on one patient who had a hysterectomy. This
was reported as showing an atrophic post-menopausal
pattern with cystic change. The glands were lined by
flattened and cuboidal epithelium. There was no mitotic
activity, epithelial ectoplasia or polyp formation. There were
7 (37) 25+ (PR19)a, 33+ (NC8), 32+ (PR24)
25 + (A67), 12 (A74), 8 (A20), 3 (A77)
No change 6 (32) 29+ (NC8), 33+ (A74), 23+ (A61), 30+
(NC48), 30 + (A23), 9 (NC34)
Progression 6 (31) All patients progressed in <8 weeks
(A48, A45, NC7, PR8, A9, NC12)
aLetters in brackets indicate response to tamoxifen when given for
advanced disease (PR, partial remission; NC, no change; PD,
progressive disease) or if given as an adjuvant therapy (A). The
numbers in the brackets indicate duration of treatment with
tamoxifen.
no significant changes in body weight during treatment with
ICI 182870. Mean body weight (kg±s.d.) was 63.8+14.0
(n=13) at the beginning of treatment, 64.9+15.8 (n= 1)
after 6 months, 64.5+17.2 (n =9) after 10 months and
64.2+ 18.3 (n=9) after 16 months of treatment with ICI
182780.
Response
All 19 patients are evaluable for response to ICI 182780
(Table III). Six patients were unresponsive de novo and
showed objective evidence of disease progression within 2
months of commencing treatment. The remaining 13 patients
(69%) all responded to treatment with the specific anti-
oestrogen for a median duration of25 months. Seven patients
(37%) showed PRs for 33+, 32+, 25+, 25, 12, 8 and 3
months, and six patients (32%) showed NC responses for
33 +, 30+, 30+, 29, 23 and 9 months. Thus five patients are
still in remission and continuing treatment with ICI 182780
after 30-33 months. Responses have been observed in six of
the nine women who progressed while receiving tamoxifen as
I
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E
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treatment for advanced breast cancer as well as in seven of
the ten women who relapsed after treatment with tamoxifen
as adjuvant therapy. There appeared to be no association
between duration of treatment with tamoxifen and subse-
quent response to ICI 182780 (Table III).
Discussion
This study represents the first investigation of long-term
administration of the specific anti-oestrogen, ICI 182780, to
patients with breast cancer and demonstrates that predicted
therapeutic levels of ICI 182780, as judged from animal
experiments (Wakeling et al., 1991; Dukes et al., 1993) and
our previous short phase I study (DeFriend et al., 1994b) can
be achieved and maintained for 1 month following a single
i.m. injection of the long-acting formulation used. Treatment
with ICI 182780 was associated with minor effects on serum
hormones and lipid levels, produced few side-effects and
resulted in a high response rate after tamoxifen failure,
together with a median reponse duration of 25 months.
Pharmacokinetic data concerning the release characteris-
tics of the drug into the serum in this study were found to be
similar to those previously demonstrated in adult female
monkeys (Dukes et al., 1993). From studies on inhibition of
endometrial proliferation in the monkey and inhibition of
tumour proliferation in a previous phase I study, it was
predicted that serum levels of ICI 182780 in the range of 2-
3 ng ml-' were consistent with a therapeutic effect in patients
with advanced breast cancer. However, a direct pharmaco-
kinetic-pharmacodynamic link is not proven with the few
patients studied to date. Serum drug concentrations in excess
of this were observed with the 250 mg dose used in the
present study for most of the first and all of the sixth month.
However, there was evidence of drug accumulation after
multiple dosing, such that after 6 months treatment there was
an 80% increase in mean end of month drug levels and a
50% increase in the AUC compared with data from month 1.
These data suggest that lower doses of the drug may be
effective in maintaining therapeutic serum drug levels,
although further clinical studies are required to confirm this
hypothesis.
Previous animal studies with ICI 182780 have shown that
the activity of specific anti-oestrogens may vary between
different oestrogen target sites (Wakeling, 1993). In the
present study, we have attempted to obtain preliminary data
on the effects of long-term administration of ICI 182780 on
the pituitary gland/hypothalamus, the liver and the endome-
trium. Serum gonadotrophin levels significantly increased
during the first 3 months of treatment with ICI 182780 and
then remained stable thereafter. This change is in contra-
distinction to that seen with the triphenylethylene anti-
oestrogen, tamoxifen, which reduces serum levels of FSH
and LH in post-menopausal patients because of its
oestrogenic effect on the pituitary gland and hypothalamus
(Willis et al., 1977). All but four patients in the present study
were treated with tamoxifen up until treatment with ICI
182780 was initiated. Levels of FSH and LH at this time were
below the range for normal post-menopausal women, which
is attributable to previous therapy with tamoxifen. The rise of
gonadotrophins during the first 3 months of treatment with
ICI 182780 may therefore have been a passive effect caused
by cessation of tamoxifen rather than an active anti-
oestrogen effect of the new agent. The fact that gonado-
trophin levels rose to well within post-menopausal values and
then remained stable would support the view that ICI 182780
is without effect on gonadotrophin levels. This apparent lack
ofactivity of the specific anti-oestrogen on the hypothalamus
and pituitary gland is further supported by the findings that
ICI 182780 did not initiate or exacerbate hot flushes or
sweats in the present study, nor did it produce significant
changes in serum prolactin levels.
Treatment with tamoxifen has been reported to increase
serum levels of SHBG secondary to a probable oestrogenic
effect of tamoxifen on the liver (Sakai et al., 1978). The
levels of SHBG in some of our patients before starting
therapy with ICI 182780 were high, consistent with the
oestrogenic effect of prior treatment with tamoxifen.
Following commencement of treatment with ICI 182780, a
slight decline in SHBG levels occurred, consistent with
tamoxifen withdrawal, but thereafter median levels of SHBG
remained in the middle of the normal range for our
laboratory, suggesting that the specific anti-oestrogen may
have little effect on SHBG synthesis in the liver. A lack of
effect of the compound on the liver is further suggested by
evaluation of lipid changes. Tamoxifen is known to reduce
levels of cholesterol and LDL cholesterol and is associated
with an increase in triglycerides and HDL cholesterol
consistent with an oestrogenic effect on the liver (Bertelli
et al., 1988; Love et al. 1990). None of these changes
reported during treatment with tamoxifen were observed
during the present study. This would further suggest that
ICI 182780 is peripherally selective with respect to the liver.
However we cannot explain why there was not the expected
changes in lipids as patients came off tamoxifen.
The lack of apparent adverse effects of ICI 182780 seen in
the present study would, if confirmed in future larger trials,
give the specific anti-oestrogen potential advantages over
currently available second-line endocrine agents. The ob-
served lack of effect of ICI 182780 on body weight over a
period of study that ranged from 6 to 16 months would give
the new agent a potential advantage over megestrol acetate,
the most widely used second-line endocrine therapy in breast
cancer, which resulted in weight gain of >5% ofbody weight
in 25% ofpatients in one study (Willemse et al., 1990) and a
median weight gain of 9 lbs after 180 days of treatment in
another (Cruz et al., 1990). Overall, 83% ofpatients reported
side-effects during treatment with megestrol acetate (Willemse
et al., 1990).
The most troublesome side-effects of tamoxifen, the
current first-line endocrine therapy of choice, are the
inception or exacerbation of hot flushes and sweats and the
initiation of vaginal discharge. As already stated, ICI 182780
did not induce or exacerbate hot flushes or sweats in the
present study and furthermore did not cause symptoms of
vaginal dryness or altered libido. Since the vaginal discharge
experienced by 10-33% ofpatients during tamoxifen therapy
is thought to be related to the oestrogenic activity of the
drug, we expected ICI 182780 to be associated with vaginal
dryness and irritation; the fact that this did not occur further
suggests that ICI 182780 may be peripherally selective with
respect to oestrogen target-site activity.
Serial measurements of endometrial thickness were
obtained from five patients during treatment with ICI
182780. Before commencing treatment with the specific anti-
oestrogen, the endometrial thickness in all five patients was
greater than that found in the normal post-menopausal
uterus. We assume that the overall 'thickening' we detected
was related to previous tamoxifen therapy as this phenom-
enon has been widely reported. During the relatively short
duration ofthe present study, there was no further increase in
thickening during treatment with ICI 182780. However there
was also no decline in thickness as might be expected
following treatment with a specific anti-oestrogen. Whether
this finding reflected a true increase in endometrial thickness
or an additional swelling of the myometrium, which has also
been described in women taking tamoxifen (Cohen et al.,
1994), is not known as we did not perform endometrial
biopsies. In the one patient where hysterectomy was
performed, histology showed no thickening of the endome-
trium, rather that it was flattened, atrophic and with no
mitotic activity. From the results of the sequential ultrasound
data and the endometrial histology, it is not clear why ICI
182780 does not result in thinning of the endometrium. In
primates (Dukes et al., 1993) and in short-term studies in
women (Thomas et al., 1993) ICI 182780 inhibited
endometrial proliferation at similar serum concentrations to
those seen in the present study. It is possible, therefore, thatICI 182780 and advanced breast cancer
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ICI 182780 inhibits further endometrial proliferation but does
not cause regression of pre-existing hypertrophied endome-
trial tissue. If a similar inhibitory effect of ICI 182780 on
endometrial proliferation is proven in future longer term
clinical studies, it would suggest a further potential
therapeutic advantage of specific anti-oestrogens over partial
agonist agents, as the oestrogenic activity of tamoxifen on the
female genital tract has led to concerns over its potential to
induce endometrial hyperplasia or carcinoma (Fornander et
al., 1989) in patients receiving adjuvant therapy or entering
breast cancer prevention trials.
The response data in the present study show that patients
with advanced breast cancer have a high chance of response
for prolonged durations to a specific anti-oestrogen after
failure of treatment with a partial agonist anti-oestrogen. In
the highly selected group of patients reported here, there
appeared to be no cross-resistence between ICI 182780 and
taxomifen in 69% of patients and the median duration of
reponse was 25 months. In contrast, clinical studies in which
tamoxifen-resistant patients were treated with another
triphenylethylene anti-oestrogen, toremifene, demonstrated
much higher rates of cross-resistance (Vogel et al., 1993
and references therein).
ICI 182780 is thought to act exclusively as an anti-
oestrogen via the ER (Wakeling et al., 1991). Responses to
treatment with ICI 182780 after progression on tamoxifen in
such patients suggests that tamoxifen failure may be because
of the intrinsic agonist activity of tamoxifen or one of its
oestrogenic metabolites (Simon et al., 1984; Gottardis et al.,
1989; Osborne et al., 1991; Howell et al., 1992; DeFriend et
al., 1994a) or because tamoxifen is, in some way, sequestered
from the ER (Pavlick et al., 1992; Wolfe et al., 1993) allowing
endogenous oestradiol to recommence tumour stimulation.
Tamoxifen has been shown to stimulate the growth of
human mammary tumour cell lines when grown both in vitro
(Lykkesfeldt and Sorenson, 1992) and in vivo as xenografts in
nude mice (Gottardis et al., 1989). We have reported
preliminary data demonstrating tamoxifen-induced growth
stimulation in vitro of breast cancer cells harvested from
patients with advanced disease at the time of failure of
tamoxifen treatment (DeFriend et al., 1994a). In all the
experiments cited above, the specific anti-oestrogen was able
to reverse the stimulatory effects of tamoxifen. In addition,
we and others have demonstrated so-called withdrawal
responses in breast cancer patients after stopping treatment
with tamoxifen at the time of tumour progression, further
suggesting tumour stimulation by tamoxifen as a possible
cause of treatment failure (Howell et al., 1992). However, in
most studies withdrawal responses occur in only one-third or
less ofpatients and thus tamoxifen withdrawal responses are
unlikely to account for all the responses seen after treatment
with ICI 182780 in the current study.
Alternatively, there is also evidence that tamoxifen may be
either excluded from tumour cells (Osborne et al., 1991) or
possibly sequestered away from the ER at alternative
intracellular binding sites (Pavlick et al., 1992), allowing
endogenous oestrogens to restimulate tumour growth and
cause treatment failure. Under these circumstances tumours
would be expected to retain responsiveness to a specific anti-
oestrogen and in in vitro studies, human mammary tumour
cell lines that are unresponsive to tamoxifen have been shown
to retain sensitivity to the antiproliferative effects of ICI
182780 (Brunner et al., Lykkesfeldt et al., 1994; Coopman et
al., 1994).
As neither of the two possible mechanisms of tamoxifen
resistance outlined above (tamoxifen agonism or tamoxifen
sequestration) would be expected to be shared by the
chemically distinct, specific anti-oestrogens, the new agents
have the potential to improve the rate and/or duration of
response to anti-oestrogen therapy in breast cancer.
Furthermore, there is experimental evidence to suggest that
specific anti-oestrogens may also prove to be more effective
than alternative strategies for oestrogen deprivation of
human breast tumours, including the use of gonadotrophin-
releasing hormone analogues and aromatase inhibitors.
These alternative treatments profoundly reduce but do not
completely abolish oestrogen synthesis and small amounts of
circulating oestrogen remain detectable in the serum of
patients. Although these very low levels of oestrogen may
be insufficient to produce any significant directly mitogenic
effects in breast cancer cells, recent experimental studies have
shown that small concentrations of oestradiol can act
synergistically to amplify the effects of other growth-
promoting pathways such as epidermal growth factor/
transforming growth factor alpha (EGF/TGF-a), insulin-like
growth factor (IGF)-1 and the fibroblast growth factor family
(Stewart et al., 1990; Westley and May, 1991). In addition,
EGF and dopamine have been found to activate ER
signalling pathways in the complete absence of ligand and
it has been shown that an EGF-specific tyrosine kinase
inhibitor can inhibit both proliferation and expression of
several oestrogen-responsive genes by MCF-7 cells under
conditions of complete oestrogen withdrawal (Reddy et al.,
1992; Wakeling et al., 1994).
Specific anti-oestrogens produce both potent inhibition of
ER activation by oestrogen and reduction of ER levels. In in
vivo studies, they have been found to reduce the growth rate
of breast cancer cells, grown in culture media containing no
exogenous oestrogens, and to inhibit activation of ER
signalling pathways by EGF and dopamine (Power et al.,
1991; Ignar-Trowbridge et al., 1992). Specific anti-oestrogens
may therefore be superior to other methods of oestrogen
withdrawal for the treatment of breast cancer, as they appear
to prevent activation of growth pathways by remaining small
amounts of oestrogen and also to block constitutive ER
activation, stimulated by non-oestrogen-mediated pathways.
We conclude from the results of this preliminary study
that the pure anti-oestrogen, ICI 182780, is well tolerated
during long-term treatment and is active as an anti-tumour
agent in patients with advanced breast cancer who have
previously relapsed on tamoxifen. At the dose used, there was
accumulation of the drug over time and thus lower doses
than those administered in this study may be as effective. The
evident lack of cross-resistance between tamoxifen and ICI
182780 is in accordance with the hypothesis that the agonist
activity or sequestration of tamoxifen may cause some
treatment failures in patients with advanced breast cancer
and results in restimulation of tumour growth. Since ICI
182780 appears devoid of agonist activity, treatment failure
via a similar mechanism should not occur, and it is possible,
therefore, that this new agent may improve the rate and
duration of response in patients with advanced breast cancer.
However, further studies are required to confirm the response
rate and also to determine the long-term effects of this agent
on bone, plasma lipids and the endometrium.
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